85%Confidence
0Views
FDASource
2026-04-11Date
Summary
Teva faces a Class II recall for Octreotide Acetate due to sterility concerns from a contract manufacturer in Greece, indicating supply chain quality control failures. This may disrupt patient access and lead to reputational damage, potentially affecting Teva's revenue from this product.
Actionable: Monitor Teva's stock for potential impacts from recall-related costs and regulatory scrutiny.
AI Confidence: 85%
Data Points
firmTeva Pharmaceuticals USA, Inc
classificationClass II
statusOngoing
distributionNationwide in the USA
productOctreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 20 mg, Single-dose 8 mL vial, Rx only, Manufactured in Greece BY: Pharmat
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now